ABSTRACT The presence of specific benzodiazepine binding sites in the hearts of dogs and human beings was demonstrated in vivo by a noninvasive method, positron emission tomography (PET). An antagonist of the peripheral-type benzodiazepine binding site, PK 1 1 195, was labeled with carbon-1 1, a short-lived positron emitter. When injected at high specific activity, 1C-PK l 1195 was concentrated in the myocardium. As increasing amounts of unlabeled PK 11195 were added to the radioactive ligand, the myocardial ligand concentration was proportional to myocardial regional perfusion up to quantities of 40 nmol/kg body weight. Above 40 nmol/kg the ligand concentration reached a maximum value (6000 pmol/cm3), which could be considered as the total number of binding sites per unit heart volume. The specificity of 1 'C-PK 11195 binding to canine heart was demonstrated from a study on the inhibition of binding for radioligand by an excess of several agonists or antagonists of benzodiazepine receptor. The distribution and specificity of 1 1C-PK 11 195 was similar in dogs and in human beings.
binding sites are pharmacologic receptors coupled to calcium channels in guinea pig papillary muscle'3 and that PK 1 1 195, a compound devoid of activity in heart muscle, is an antagonist of the peripheral-type benzodiazepine receptor.
It thus seemed interesting to characterize the peripheral-type benzodiazepine receptor noninvasively in vivo in the canine and human heart with PK 11195 as ligand. Noninvasive investigation of cardiac receptors was impossible until the introduction of labeling methods using carbon-11, a short-lived cyclotron isotope, and of positron emission tomography (PET). PET is a vizualization technique that permits quantitative measurements in vivo of local perfusion, metabolism, pharmacology, and biochemistry in the heart by external detection. 14' 15 It thus offers the possibility of characterizing changes in receptor binding properties as well as regional receptor density in the hearts of intact animals and ultimately in human cardiac diseases. 16 17 We report here a first attempt to characterize the peripheral-type benzodiazepine receptor in the canine and human heart by PET and " C-PK 11195.
THERAPY AND PREVENTION-RECEPTOR LOCALIZATION Methods
Preparation of 11C-PK 11195. The "C-PK 11195 synthesis method has been described elsewhere.'8 'CO2 was produced in a medical cyclotron and I"C-methyl iodide used as the labeled precursor. N-I'C-methyl, N (-methyl-l-propyl), 2 (chloro-2 phenyl)-1 isoquinolinecarboxamide -3 was produced in about 45 min at high specific activity (around 800 Ci/mmol). The radiochemical purity, as assayed by high-pressure liquid chromatography, was better than 99%. Sterility and apyrogenicity were checked.
Animal studies. Twenty-four experiments were carried out on 10 beagles (eight females, two males) weighing 10 to 18 kg. Each animal was anesthetized with sodium pentobarbital (25 mg/kg) 2 In four experiments 50, 100, 200, and 2500 ,ag/kg unlabeled PK 11195 was rapidly injected 30 min after the injection of "'C-PK 1 1 195 to inhibit the binding of the labeled ligand from its specific binding sites. In one experiment 200 gg/kg PK 11195 was injected 110 min after the " C-PK 11195 injection. The benzodiazepine binding sites were further characterized in nine experiments by injection of various amounts of unlabeled agonist or antagonist 30 min after that of " C-PK 11195. The same protocol was used in two other experiments to study the effect of "1C-PK 11195 solvent and the effect of the norderivative (PK 13042) on the binding of ' 1C-PK 1 1 195 . In five other experiments, the effect of specific activity variations was studied by addition of unlabeled PK 1 1 195 (100, 160, 250, 300, and 500 nmol/kg) to "C-PK 11195.
Human studies. Seven normal male volunteers (22 to 35 years old) were positioned in the ECAT II camera and an 18-gauge needle was placed in an antecubital vein. Transmission scans were recorded for later attenuation correction of emission data. Seven to 21 mCi (259 to 777 MBq) of "'C-PK 1 1 195 was injected rapidly. Specific activities at the time of injection ranged from 41 to 580 mCi/,umol. Myocardial scans were obtained as described above. To study the binding inhibition of " C-PK 11195 on its specific binding sites, 100, 200, or 500 ,jg/kg PK 11195 was rapidly injected in four experiments 30 min after the "C-PK 1 1 195 injection. The electrocardiogram was monitored continuously in each subject. Radioactive concentrations were calculated in three regions of interest for each scan as described above.
Results
Animal studies. Lung and heart images obtained at different times after injection of' 'C-PK 11 195 in a dog (No. PKC 05) are shown in figure 1. During the first minutes the activity was concentrated in the lungs, but after 5 min activity in the myocardium became higher than that in the lung (figure 1, 2). Blood activity was soon negligible and the blood pool was never visualized except during the first pass. Thirty minutes after injection, activity in the heart remained fairly constant and that in the lung was undetectable ( figure 1, 3 ). In the same dog, a large dose of unlabeled PK 1 1195 (200 ,ug/kg) was rapidly injected at 31 min. Competition between labeled and unlabeled ligand for the same benzodiazepine binding sites led to a fall in the myocardium 'C-PK 11195 activity ( figure 1, 4) .
The concentration of PK 11195 in the heart (expressed as pmol/cm3) measured 20 mn after injection was proportional to the amount of PK 1 1195 injected intravenously up to doses of 40 nmol/kg body weight (figure 2, inset) (y = 18.96 x -3.01, r = .999).
Above this dose the concentration in the heart increased nonlinearly with the amount of ligand injected to reach a maximum of about 6000 pmol/cm3 (figure 2); the "1C-PK 11195 concentration then became independent of the amount of ligand injected.
The kinetics of''C-PK 11195 binding inhibition on its binding sites by unlabeled PK 1 1 195 is shown in figure 3 . After a bolus injection of tracerat high specif- Human studies. Figure 5 shows the cardiac image obtained after injection of 12 Percentages of 'C-PK 11195 binding inhibition on nmol/kg (r .991). For the same injected doses of C-PK 11195 (range 0.3 to 2.50 nmol/kg body weight), the concentration of PK l 1195 in the heart was similar in dogs and human beings (range 5 to 55 pmol/cm3).
Discussion
The existence of specific benzodiazepine binding sites in the canine and human heart is demonstrated in this study in vivo using PET, a noninvasive imaging technique that provides information analogous to that obtained by autoradiography in vitro, with the added advantage that myocardial receptors may be studied under physiologic conditions.16, 17. 19 The demonstration of peripheral-type benzodiazepine binding sites was first made in vitro with 3H-diazepam.6 Specific high-affinity 3H-diazepam binding was shown in peripheral organs such as the kidney, lung, liver, heart, skeletal and ileal muscle, mast cells, spinal cord, and human circulating lymphocytes. 20 The peripheral-type site has also been shown to predominate in various cultured neural cells. the two ligands seem to act differently; 31H-PK 11195 binding was entropy-driven, whereas 3H-RO 54864 was enthalpy-driven. 12 Furthermore, PK 11195 reversed the action of RO 5-4864 on the guinea pig papillary muscle; the shorter duration of intracellular action potential and muscle contractility induced by RO 5-4864 were antagonized by PK 11195 but not by the selective antagonist of the central-type benzodiazepine receptor, RO 15-1788.'3 The guinea pig cardiac benzodiazepine binding sites of the peripheral type were shown to be pharmacologic receptors,13 which were coupled to calcium channels in the papillary muscle.21 PK 11195, a potent antagonist of the benzodiazepine receptor in the heart, could therefore be an ideal ligand to characterize this receptor in vivo by external detection with PET. PK 11195 was thus labeled with carbon-11 at very high specific activity and injected intravenously in dogs and human beings. An initial uptake of 'C-PK 1 1 195 was seen in the lung, followed by a high uptake in the heart. Benzodiazepine binding sites were uniformly distributed in the canine and human hearts. A few minutes after injection, "C-PK 11195 distribution in the heart was similar to that of regional myocardial blood flow. The amount of PK 1 1 195 found in the heart was proportional to the quantity injected at values below 40 nmol/kg. The slope of the regression line ( X 10-3) is equal to the ratio of myocardial blood flow per cubic centimeter of tissue to the cardiac output per kilogram of body weight. ' Above 40 nmol/kg, however, the curve showed a plateau because of saturation of the benzodiazepine binding sites. This result agrees with the mathematical model of a ligand receptor interaction studied in vivo,à nd a similar curve was also obtained in human beings from a PET study on the muscarinic acetylcholine receptor. 7 From the PK 1 1195 concentration, the number of benzodiazepine binding sites in the dog ventricular myocardium (RT) was found to be around 6000 pmol/cm3 of tissue. This value is probably overestimated, since one fraction of PK 11195 corresponded to nonspecific binding and another to circulating PK 11195. This latter fraction could be estimated at 150 pmol/cm3 of tissue from the "C-PK 11195 blood concentrations and from an estimation of the fractional volume of blood in the heart. An additional cause of overestimation of RT was the factor used to correct for the partial volume effect as discussed above. The receptor density found in vivo in dogs could be compared with that found in heart homogenates of rats (4420 pmol/g protein), dogs (3125), and baboons (1 1,330) (B. Maziere, unpublished data). Several criteria, in addition to the specific regional distribution of binding sites, must be met for identification of the ligand receptor interaction by PET. Saturability of the ligand receptor complex was demonstrated by two kinds of experiments. In the binding inhibition experiments, excess cold agonist or antagonist was injected intravenously 30 min after injection of the labeled ligand. The radioactivity then decreased rapidly with time because of the competitive inhibition between tracer and excess unlabeled ligand. The dissociation rate constant of the ligand-receptor complex k_ was calculated from the initial part of the "displacement curve" as previously described'6 and found to be 0. 15 min-'. The k l value for the dissociation of 3H-PK 1 1 195 measured in vitro on rat heart homogenates (0.49 min ') was very much the same. 12 "C-PK 1 1 195 binding was inhibited by unlabeled PK 1 1 195 and by other ligands that compete for peripheral-type sites, but not by those that bind only to brain-type sites such as RO 15-1788 . Furthermore, the order of potency in the "C-PK 11195 inhibition was similar to that found in rat heart with 3H-PK 11195.20 The maximum binding inhibition, 68%, was measured 5 min after injection of the unlabeled compound. These results;suggest that the investigation of benzodiazepine receptors with " C-PK 11195 and PET might be very useful for the investigation of cardiac ischemia in human beings.
